• Total deal value in obesity and diabetes drug R&D partnerships hit a record $20.2 billion in 2025.
  • Mergers and acquisitions significantly increased, offsetting declines in IPO activity and venture capital investment.

Market Insights

  • The rising deal value reflects the high strategic importance and commercial potential of obesity and diabetes therapeutics.
  • With over 1 billion people globally affected by obesity, investment focus remains strong on scalable treatment innovations.

Industry Impact

  • This record-setting dealmaking climate may accelerate therapeutic development and market competition.
  • Investors and stakeholders watch closely as emerging treatments face real-world scaling challenges.

Source: medcitynews.com